NICE backs wider use of MSD’s Simponi
Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.
Read More
Tag: golimumab
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
